BodyCoding

Research

Track clinical research, regulatory updates, and primary sources on GLP‑1 and metabolism.

Research Body Education Agent Projects

November 2026

MonTueWedThuFriSatSun

Research

31 cases
Research

The effect of glucagon-like peptide-1 receptor agonists versus metformin on pregnancy rates in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized trials

Researchers conducted a systematic review and meta-analysis of randomized controlled trials comparing GLP-1 receptor agonist-based therapy with metformin monotherapy in women with polycystic ovary syndrome. The results showed that GLP-1 receptor agonist-based treatment did not significantly improve overall pregnancy rates but was associated with an increase in natural pregnancy rates, with no significant effect on IVF pregnancy rates.

Research

Implication of Perivascular Adipose Tissue as a Potential Therapeutic Target for the Vascular Defensive Actions of Incretin-Based Therapies and SGLT2 Inhibitors

This review explores the potential mechanisms by which incretin-based therapies and SGLT2 inhibitors provide cardiovascular protection. The authors identify perivascular adipose tissue (PVAT) as a key regulator of vascular tone and inflammation. While these therapies offer cardiovascular benefits beyond glucose lowering, the precise mechanisms remain unclear. This review proposes PVAT and its signaling as novel therapeutic targets to explain how these treatments provide vascular protection.

Research

GLP-1-based therapies for reduction of heart failure and cardiovascular outcomes: A systematic review and meta-analysis of randomized controlled trials

Researchers conducted a systematic review and meta-analysis of randomized controlled trials to evaluate the effects of GLP-1-based therapies on cardiovascular mortality, heart failure hospitalization, unstable angina hospitalization, nonfatal myocardial infarction, and nonfatal stroke. The analysis included 11 trials with 81,948 participants. Results showed that GLP-1-based therapy significantly reduced cardiovascular mortality, heart failure hospitalization, nonfatal myocardial infarction, and nonfatal stroke. However, no significant benefit was observed for unstable angina hospitalization. Heterogeneity was observed for some outcomes.

Research

Loss of Female Cardiovascular Protection in Diabetes: From Mechanisms to Intervention

This review explores the mechanisms behind the increased cardiovascular risk in women with diabetes, noting that women with type 1 or type 2 diabetes have a higher risk than men. The article analyzes the paradoxical relationship between chronic hyperglycemia and estrogen signaling, as well as the contribution of sex-related differences in body composition. It highlights the importance of lifestyle interventions and suggests investigating sex-specific cardiovascular responses to treatments like GLP-1 receptor agonists and SGLT2 inhibitors.

Research

Papillary thyroid carcinoma discovered in a patient on semaglutide therapy for metabolic syndrome: a case presentation and review of current evidence

Researchers report a case of papillary thyroid carcinoma (PTC) discovered incidentally in a patient with metabolic syndrome and obesity after several years of semaglutide treatment. The patient underwent thyroidectomy, and pathology confirmed a unifocal classic variant PTC. The study notes that while this case highlights an important clinical scenario, it does not provide evidence of causation, and current human data continues to support the safety of semaglutide regarding thyroid cancer risk.

Research

Sustained metabolic control in latent autoimmune diabetes in adults (LADA) with semaglutide therapy in a patient with multiple autoimmune comorbidities: a case report and literature review

Researchers reported a case of a 55-year-old woman initially diagnosed with type 2 diabetes who was later reclassified as LADA due to positive autoantibodies. After discontinuing metformin and initiating semaglutide, the patient maintained durable glycemic control, significant weight loss, and stable beta-cell function without insulin over five years. A literature review also highlighted limited evidence for GLP-1 receptor agonists in LADA.

Research

Combination pharmacotherapy for MASH: Potential synergistic approaches

This review discusses potential synergistic approaches for combination pharmacotherapy in metabolic dysfunction-associated steatotic liver disease (MASLD). The authors describe the spectrum of MASLD and the challenges in demonstrating efficacy of single agents in phase 3 trials. The review highlights the recent conditional approval of monotherapies targeting metabolic pathways, such as resmetirom and semaglutide, and discusses the rationale for combining these agents.

Research

Potential protective associations of antidiabetic and lipid-lowering therapies with retinal vein occlusion risk: a systematic review and meta-analysis

Researchers evaluated the association between systemically administered antidiabetic or lipid-lowering agents and retinal vein occlusion (RVO). The study included six cohort studies and four case-control studies involving over 2 million adults. Meta-analysis results suggest that statin use consistently reduced RVO risk. Metformin monotherapy and GLP-1 receptor agonists showed signals of benefit, while findings for SGLT-2 inhibitors were inconsistent. These findings require confirmation in prospective studies.

Research

Predicting response to GLP-1-based therapy in MASLD/MASH: an evidence-tiered, endpoint-specific framework built on host genotype and gut microbial features

This review examines the variability in benefit from incretin-based therapy for metabolic dysfunction-associated steatohepatitis (MASH). It proposes that liver benefits from GLP-1 receptor agonists are indirect, mediated by weight loss and gut-liver signaling. The authors assemble evidence on host genotype and gut microbial features into a framework to predict patient response, grading findings by evidence maturity and separating liver and cardiovascular benefits.

Research

What was the primary endpoint in SELECT?

Published in 2023, this randomized trial enrolled adults with overweight or obesity and established cardiovascular disease without diabetes. Its primary endpoint covered major cardiovascular events.

SELECT paper in the University College London repositoryRead case ↗
Research

Efficacy and Safety of Semaglutide According to Frailty Status

Researchers analyzed secondary data from the SELECT randomized clinical trial to evaluate whether frailty status modifies the efficacy and safety of semaglutide in adults with cardiovascular disease and overweight/obesity. Participants were categorized by a frailty index into not frail, more frail, and most frail groups. The study compared semaglutide with placebo. Results indicated that semaglutide benefits on the primary cardiovascular outcome were consistent across frailty categories, and the improvement in health-related quality of life was greater in those with higher frailty.

Research

GLP-1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications

This narrative review appraises evidence regarding seven serious adverse events linked to GLP-1 receptor agonists, including thyroid cancer, acute pancreatitis, gallbladder and biliary disease, and others. The authors consider evidence from mechanistic studies, spontaneous reports, randomized trials, and cohort studies. For events such as thyroid cancer and acute pancreatitis, evidence regarding causality remains uncertain. The authors note that because these events are rare, even substantial relative risk increases generally correspond to small absolute risk increases in broad populations.

Research

Efficacy and safety of domestic semaglutide injection in patients with type 2 diabetes mellitus inadequately controlled with metformin

This multicenter, randomized, positive-controlled phase 3 equivalence clinical trial evaluated the efficacy and safety of domestic semaglutide injection in patients with type 2 diabetes mellitus inadequately controlled with metformin. Patients were randomized to an experimental group receiving domestic semaglutide injection and a control group receiving original semaglutide injection. The study compared the two treatments over 32 weeks.

Research

Context-dependent functions of insulin, IGF, and GLP signaling in inflammatory bowel disease

This review summarizes current knowledge regarding the biological functions and molecular mechanisms of insulin, IGFs, IGFBPs, and GLPs in IBD. IBD is a chronic relapsing inflammatory disorder of the gastrointestinal tract. Insulin signaling plays context-dependent roles in IBD by regulating glucose metabolism, epithelial repair, and inflammatory responses. The IGF axis is also profoundly altered during active IBD. GLP signaling further integrates metabolism with intestinal immunity; GLP-1 receptor agonists exhibit anti-inflammatory, metabolic, and microbiota-modulating effects. Emerging preclinical and observational clinical studies suggest that GLP-based therapies may improve disease outcomes, although prospective randomized trials are still required.

Research

GLP-1 receptor agonists for people with type 2 diabetes and peripheral artery disease: reducing uncertainty in clinical practice

Researchers reviewed the use of GLP-1 receptor agonists in patients with type 2 diabetes and peripheral artery disease. Findings indicate that semaglutide is better than placebo in reducing PAD events, while liraglutide and semaglutide may increase walking distance. Observational studies also show that GLP-1RA use reduces MALE risk. Although dedicated RCTs for hard limb outcomes are lacking, current evidence supports choosing proven effective GLP-1RAs to improve metabolic and walking capacity.

Research

GLP-1/GLP-1R signalling in infectious diseases: basic biology, immunometabolic mechanisms, and therapeutic translation

This narrative review evaluates GLP-1/GLP-1R signalling in infection, assessing the effects of GLP-1 receptor agonists (GLP-1RAs) on metabolism, immunity, and inflammation. The study distinguishes pathogen models from endotoxin models and analyzes receptor-dependent versus systemic effects. The review indicates that GLP-1RAs consistently attenuate inflammation and tissue injury but have variable effects on pathogen clearance. Current human evidence is mainly from observational studies, lacking data on treatment initiation during acute infection.

Research

Comparative effects of pharmacological treatment for weight gain in patients treated with antipsychotics

Researchers conducted a systematic review and network meta-analysis of randomized controlled trials to compare drugs for reducing weight gain caused by antipsychotic medications. The analysis included 27 studies evaluating 17 drugs. Results showed that nizatidine and metformin were superior to placebo in short-term interventions, while liraglutide, exenatide, metformin, and samidorphan showed significant benefits in long-term interventions. Liraglutide ranked highest in SUCRA analysis.

Research

Sex differences in cardiovascular-kidney-metabolic syndrome: the FINE-HEART pooled analysis.

Researchers pooled individual participant-level data from trials of chronic kidney disease and type 2 diabetes and a trial of heart failure to compare risks between men and women with cardiovascular-kidney-metabolic syndrome. Findings indicated women were slightly older and less likely to receive common CKM therapies. During follow-up, both groups had similar risks of HF hospitalization or cardiovascular death, but women had lower all-cause mortality. Finerenone showed consistent benefits in both sexes.

Research

Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists: A systematic review

Researchers evaluated cardiovascular outcome trials for glucagon-like peptide-1 receptor agonists (GLP1RAs) in patients with type 2 diabetes, overweight/obesity with atherosclerotic cardiovascular disease, and obesity with heart failure with preserved ejection fraction. The review found that GLP1RA therapy consistently reduced major adverse cardiovascular events in patients with type 2 diabetes. Weekly subcutaneous semaglutide lowered the risk of major adverse cardiovascular events in patients with overweight/obesity and atherosclerotic cardiovascular disease without type 2 diabetes. Tirzepatide lowered the composite endpoint of adverse heart failure events and cardiovascular death in patients with obesity and heart failure with preserved ejection fraction.

Research

Role of GLP-1 receptor agonists in the prevention and treatment of obesity-related cancer

This review discusses the role of GLP-1 receptor agonists in improving glycemic control and promoting weight loss, and explores their potential anticancer effects by modulating pathways like insulin signaling, inflammation, and cellular proliferation. Current evidence from observational and secondary analyses suggests potential protective effects against several cancers, including prostate and breast cancer, through both weight-dependent and independent mechanisms. However, the absence of large-scale randomized controlled trials with cancer-specific endpoints remains a critical limitation, and safety concerns warrant vigilance.

Research

Obesity, Weight Loss, and Rhinology and Allergy

This review explores the link between obesity and rhinologic and allergic diseases, noting that obesity is a common comorbidity and increases the risk and severity of chronic rhinosinusitis through adipokine-mediated inflammation. The article summarizes current evidence and highlights the potential clinical implications of weight loss interventions for improving sinonasal disease burden and surgical outcomes.

Research

Attenuation of Fasting and Postprandial Glucose Exposure by Standardized Salacia reticulata Extract in Adults with Prediabetes

This randomized, double-blind, placebo-controlled trial evaluated the effects of a standardized Salacia reticulata extract on fasting and postprandial glucose exposure in adults with prediabetes. Participants with dual fasting and postprandial glycemic impairments were randomly assigned to receive the extract or placebo for 12 weeks. Compared with placebo, the extract significantly reduced fasting and postprandial glucose levels and glucose spikes, while also lowering HbA1c and triglycerides.

Research

Pomegranate Juice Induces Similar Glycemic but Distinct Incretin Responses Compared with Sugar Water

This randomized, controlled crossover trial compared acute glycemic and incretin responses after consuming isocaloric pomegranate juice and sugar water. Researchers studied 42 adults on a standardized low-polyphenol diet who consumed the beverages in random order. Findings indicate that pomegranate juice produced similar glycemic responses to sugar water but elicited significantly lower GIP responses.

Research

Read a GLP‑1 drug labeling update

On November 9, 2026, the U.S. FDA announced required GLP‑1 receptor agonist labeling changes concerning the potential risk of NAION, a rare optic nerve disorder.

U.S. FDA drug safety communicationRead case ↗
Research

What did the early CTX310 study measure?

On November 9, 2026, CRISPR Therapeutics announced Phase 1b results for CTX310, reporting changes in blood lipid measures among participants with severe hypertriglyceridemia.

CRISPR Therapeutics announcementRead case ↗

Case

Open case page

Submit a case

Submit a project, learning resource, or study with a public source. Approved cases appear on the calendar. Use public or synthetic data.

Generate a case draft

Choose a public learning topic to draft a title, summary, and a point to verify. You can edit the draft before submitting.